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Abstract
Background: DNA-methyltransferase (DNMT)-3A plays an important role in the development of embryogenesis
and the generation of aberrant methylation in carcinogenesis. The aim of this study was to investigate the role of
a DNMT3A promoter genetic variant on its transcriptional activity and to evaluate the association between
DNMT3A gene polymorphism and the susceptibility to gastric cancer (GC) and oesophagus carcinoma (EC) in the
Chinese population.
Methods: We selected one of the single nucleotide polymorphisms (SNPs) -448A>G in the DNMT3A promoter
region and evaluated its effect on activity using a luciferase assay. -448A>G polymorphisms of DNMT3A were
determined by polymerase chain reaction/restriction fragment length polymorphism and confirmed by sequencing.
The distribution of -448A>G polymorphisms was detected in 208 GC patients and 346 healthy controls matched
for age and gender. The distribution of -448A>G polymorphisms was also detected in 96 EC patients and matched
241 healthy controls. The association of -448A>G polymorphisms of DNMT3A and the risk of GC and EC was
evaluated by stratified analysis according to the patient’s age and gender.
Results: In a promoter assay, carriage of the -448 A allele showed a significantly higher promoter activity (> two
fold) compared with the -448G allele (P < 0.001). The allele frequency of -448A among GC patients and controls
was 32.9% versus 19.9%, respectively. Overall, we found that, compared with GG carriers, the DNMT3A -448AA
homozygotes has a > six fold increased risk of GC. Stratification analysis showed that AA homozygotes have a
more profound risk in the subgroups of individuals at the age range ≤ 60 years in GC. However, individuals with
-448AG and -448AA were not statistically significantly associated with an increased risk of EC compared with those
carried the -448GG genotype.
Conclusions: The DNMT3A -448A>G polymorphism is a novel functional SNP and contributes to its genetic
susceptibility to GC. -448A>G can be used as a stratification marker to predict an individual’s susceptibility to GC,
especially in the subgroups of individuals at the age range ≤ 60 years. However, the relative distribution of
-448A>G in EC can not be used as a prediction marker in order to evaluate an individual’s susceptibility to EC.
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Abnormal DNA methylation is thought to be a major
early event in the development of tumours where DNA
methyltransferases (DNMTs), DNMT1, DNMT3A and
DNMT3B have been identified as DNA methylation
functional enzymes in eukaryotic cells [1,2]. DNMT1,
which is often referred to as the maintenance methyl-
transferase, is responsible for maintaining pre-existing
methylation patterns during DNA replication [3,4].
DNMT3A and DNMT3B are considered to be de novo
DNA methyltranferase, which are critical in the dynamic
DNA methylation process during embryogenesis and
pathogenesis [5-7]. Aberrant promoter methylation in
various tumour suppressor genes is also involved in
human gastric cancer and oesophagus carcinoma [8-10]
and the epigenetic silencing linked this aberrant de novo
methylation of CpG islands to the overexpression of the
DNMT-3 family (DNMT3A and DNMT3B). Studies
showed that DNMT3A and DNMT3B, like DNMT1,
repress transcription in a methylation-dependent man-
ner [11,12]. Recently, Bachman et al.[ 1 3 ]s h o w e dt h a t
DNMT3A and DNMT3B repress the transcription inde-
pendence of their methylating activities and that this
repression is partially dependent upon histone deacety-
lase activity. DNMT3A associates with the histone dea-
cetylase HDAC1 using its ATRX-homology domain as a
co-repressor for RP58 [14].
Numerous studies have shown DNMT overexpression
in a variety of cancers and that it maybe involved in car-
cinogenesis [15,16]. Studies on the depletion of DNMT1
and DNMT3B in tumour cells have implied that they
play an important role in tumour development.
DNMT3A is essential for mammalian development and
is responsible for the generation of genomic methylation
patterns. Samuel et al. used knock-in transgenic mice in
order to investigate the consequences of intestinal
epithelium-specific overexpression of de novo DNMT3A
[10]. Until then it was unclear what part DNMT3A
expression and its biological function played in tumors.
The study showed that an elevated DNMT3A expres-
sion was consistent with a repressed imprinting gene
SFRP5 and promoted polyposis in APC Min mice.
DNMT3A expression in gastric cancer (GC) has only
been studied in protein levels and showed a significant
overexpression of DNMT3A in tumours while DNMT1
a n dD N M T 3 Bw e r eo n l ym o d e s t l yo v e r - e x p r e s s e d[ 1 7 ] .
DNMT3A expression and its clinical significance in
oesophagus carcinogenesis is uncertain.
Many gene polymorphisms, including some epigenetic
marker genes, have been reported to be closely asso-
ciated with a susceptibility to tumours. The polymorph-
ism in the DNMT3B promoter that plays a role in de
novo methylation has also been reported to be
associated with several tumour susceptibilities, including
gastric cancer [18,19]. However, few studies have
reported on the possible association of cancer suscept-
ibility with DNMT3A, another active de novo methyl-
transferase in mammals. To our knowledge, the
association between DNMT3A polymorphisms and clin-
ical implication of GC and esophageal carcinoma (EC)
has not been previously been reported. In the present
work, we want to determine whether a single nucleotide
polymorphism (SNP) in DNMT3A promoters contri-
butes to its increased expression and whether functional
SNP is substantially associated with cancer susceptibility.
We now show that, as with some SNPs in the DNMT3B
promoter, a SNP in DNMT3A promoter could activate
its expression at the transcription level. However, it is
important to know whether the transcriptional activa-
tion of the SNP of DNMT3A is related to tumourigen-
esis. We hypothesized that the genetic variants of
DNMT3A that are responsible for regulating the methy-
lation status of other genes are associated with an
increased risk of cancer. In this hospital-based case-con-
trol study, we genotyped a functional DNMT3A poly-
morphism and investigated the association between this
genetic variant and the risk of gastric cancer and oeso-
phagus carcinoma.
Methods
Study subjects
We recruited 208 GC patients, 96 EC patients and 346
healthy individuals (controls). Tissue samples for immu-
nohistochemical analysis were taken from 56 GC
patients. All patients were confirmed histopathologically
and samples were obtained with informed consent from
the patients and the controls and the approval of the
institutional review board at the Zhongda Hospital of
Southeast University and Jiangsu Tumor Hospital in
Jiangsu province from September 2006 to June 2008.
The controls were selected from cancer-free individuals
who visited the same hospital for regular physical exam-
inations or who volunteered to participate in the epide-
miology survey during the same period. We defined a
Table 1 Characteristics of the gastric cancer (GC) study
population
Variables Controls (n = 346) GC cases (n = 208) P value †
Age (years) 0.115
≤60 141 (40.8)* 99 (47.6)
>60 205 (59.2) 109 (52.4)
Gender 0.182
Male 243 (70.2) 157 (75.5)
Female 103 (29.8) 51 (24.5)
*Numbers in parentheses, percentage.
† P value for chi-squared test.
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from disease (including a cancer-free history) at a health
check-up. The controls were matched for age and gen-
der with the patients (Tables 1 and 2). All patients and
controls were ethnically Chinese and resided in the
Jiangsu Province of China or its surrounding regions.
SNP selection and luciferase assay
Among the candidate SNPs in DNMT3A, we focused on
an SNP in the promoter region (rs 1550117 in promo-
ter; GenBank accession No. NT_022184.14:g.4381840 A/
G). The fragments of the DNMT3A promoter region
(from -1009 to +646, transcription start site of exon 1A
counted as t1) was synthesized by polymerase chain
reaction (PCR) using genomic DNA from donors carry-
ing either the wild-type or polymorphic allele of
DNMT3A promoter region. The PCR primers used for
the exon 1A promoter regions was 5’-GGAGG-
GACCTGGAAGCATTG-3’ (forward) and 5’-TTACCG
TATGGCCGGTGGG-3’ (reverse). The PCR products
were inserted upstream of the luciferase gene in the
pGL3-basic plasmid (Promega, Madison, WI), and the
correct sequence of all clones was verified by DNA
sequencing. Promoter activity was measured using the
Lucifierase Reporter Assay System (Promega, WI, USA).
Chinese hamster ovary (CHO) cells were grown in mini-
m a le s s e n t i a lm e d i u ms u p p l e m e n t e dw i t h1 0 %f e t a l
bovine serum. 5 × 10
5 cells were plated in a six-well
plate and transfected with DNMT3A promoter SNP
fragments and empty vector pGL3-basic using Lipofecta-
mine 2000™ (Invitrogen, CA, USA). Cells were harvested
48 h post-transfection followed by the luciferase repor-
ter assay in the cell lysate. The experiment was per-
formed five times in triplicates and the results were
reported as mean ± standard deviation (SD).
DNMT3A genotyping
Samples were collected into blood vacuum tubes con-
taining ethylenediaminetetra-acetic acid (EDTA) and
stored at 4°C. Genomic DNA was extracted within 1
week of sample collection by proteinase K digestion as
previously described [20]. The transition of A>G of
DNMT3A SNP creates a TaaI restriction site, PCR-
restriction fragment length polymorphism (RFLP) was
used to detect this A-G transition in the promoter of
DNMT3A at -448A>G (GenBank accession No.
NT_022184.14:g.4381840). The DNMT3A -448A>G
polymorphisms was determined by a PCR-RFLP assay.
The PCR reaction was performed in a total of 25ìL
containing 100 ng genomic DNA, 0.1 mM dNTPs, 2.0
mM MgCl2, 10ìM primers 5’-ACACACCGCCCTCAC
CCCTT-3’ (forward), and 5’-TCCAGCAATCCCTGCC
CACA-3’ (reverse), and 1.25 U Taq polymerase (Bioco-
lor BioScience and Technology Co, Shanghai, China).
PCR cycle conditions consisted of an initial melting
step of 95°C for 5 min, followed by 32 cycles of 95°C
for 20s, 66°C for 20s, 72°C for 20s and a final exten-
sion step of 72°C for 10 min. The 358 bp fragment
was then digested with TaaI (Takara Biotechnology
Co. Ltd, Dalian, China) 2 h at 65°C, the digested pro-
ducts were separated on a 2.0% agarose gel and the
RFLP bands visualized under ultraviolet light with ethi-
dium bromide (EB) staining. The wild-type G allele
consists of a TaaI restriction site that results in three
bands (153 bp, 94 bp and 87 bp), while the variant A
allele produces four bands (247 bp, 153 bp, 94 bp and
87 bp). For quality control, genotyping analysis was
performed blind, with respect to case/control status,
and repeated twice for all subjects. The results of gen-
otyping were 100% concordant. In order to confirm
the genotyping results, randomly selected PCR-ampli-
fied DNA samples (n ≥ 3, respectively, for each geno-
type) were examined by DNA sequencing, and the
results were also 100% concordant.
Immunohistochemistry
We deparaffinized and dehydrated 4 μm-thick sections
of formalin-fixed, paraffin embedded tissue specimens
from all 56 patients. For antigen retrieval, the sections
were heated for 10 min at 120°C in an autoclave and
nonspecific reactions were blocked with 5% normal
horse serum. All sections were incubated with specific
primary antibodies that recognized DNMT3A mouse
monoclonal antibody dilution 1:75 (Imgenex, IMG-
2 6 8 A )a n df o l l o w e db yi n c u b a t i o nw i t hb i o t i n y l a t e d
secondary antibodies (anti-goat IgG, anti-mouse IgG,
dilution 1:200; Qiagen Laboratories, CA, USA) at room
temperature for 30 min. The sections were then trea-
ted with Vectastain Elite ABC reagent (Vector Labora-
tories, CA, USA). All sections were counterstained
with haematoxylin. For negative control preparations,
the primary antibody was omitted from the reaction
sequence.
Statistical analysis
Patients and controls were compared using Student’s t-
test for continuous variables and chi square (c
2)t e s tf o r
categorical variables. The Hardy-Weinberg equilibrium
Table 2 Characteristics of the esophageal cancer (EC)
study population
Variables Controls (n = 241) EC cases (n = 96) P value†
Age (years) 0.395
≤60 141 (58.5)* 61 (63.5)
>60 100 (41.5) 35 (36.5)
Gender 0.177
Male 160 (66.4) 71 (74.0)
Female 81 (33.6) 25 (26.0)
*Numbers in parentheses, percentage.
† P value for chi-squared test.
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2 test and 1° freedom
to compare the observed genotype frequencies and the
expected genotype frequencies among subjects. A com-
parison of the DNMT3A genotype and allele distribu-
tions among the study groups was performed by means
of two-sided contingency tables using c
2 test or Fischer’s
exact test. The odds ratio (OR) and 95% confidence
interval (CI) were calculated using the STATA 10.0 soft-
ware (Stata Corp, Texas, USA). P < 0.05 was considered
statistically significant.
Results
Identification of a novel functional DNMT3A
polymorphism
Several candidate SNPs in the DNMT3A gene have been
deposited in public databases http://www.ncbi.nlm.nih.
gov/SNP. Although the functional effects of these poly-
morphisms have not been elucidated, we hypothesized
that some of these variants may influence DNMT3A
activity on DNA methylation, especially those located at
the promoter region of the gene. We choose and inves-
tigated the effects of the -448A>G polymorphism on the
promoter activity of DNMT3A by luciferase assay. The
promoter activity of the -448A allele was significantly
higher (more than double) compared with the -448G
allele (P < 0.001, Figure 1).
Genotyping of SNPs
The -448A>G polymorphism in the promoter of
DNMT3A gene was first investigated in the Chinese
healthy control and patients with GC and EC by PCR-
RFLP. The DNMT3A genotypes AA, AG, and GG were
detected in the GC and EC patients and the controls.
The genotyping by PCR-RFLP analysis was completely
confirmed by DNA sequencing analysis (Figure 2). The
distributions of -448A>G genotypes in 346 healthy con-
trols are GG 63.0%, GA 34.1%, AA 2.9%, and A allele
frequency is 19.9%, shown in Table 3. The -448A>G
polymorphism of DNMT3A promoter was evaluated
and the risk related to GC groups in the case-control
study. There were no significant differences in the mean
age and gender distribution between cases and controls,
suggesting that the matching based on these two vari-
ables was adequate (Table 1). The mean age was 65
years (range, 34~80 years) for the GC patients and 71
years (range, 32~80 years) for the control subjects. All
patients and controls were successfully genotyped for
the DNMT3A polymorphism. The DNMT3A -448A>G
polymorphism was distributed in the Hardy-Weinberg
equilibrium.
The gastric cancer risks related to the DNMT3A
-448A>G genotype are shown in Tables 4 and 5. The
allele frequency of -448A among GC patients and con-
trols was 32.9% versus 19.9%, respectively. The distribu-
tions of -448A>G genotypes in the GC group (GG
49.0%, AG 36.1%, AA 14.9%) were significantly different
from those among the controls (P = 0.000). The OR and
their 95% CI were calculated using the more common
homozygous variant genotype as the reference group
(-448 GG genotypes). Compared to reference group, AA
homozygotes had a >six fold increased risk of GC (OR
6.625; 95% CI = 3.128-14.034, P = 0.000). When the
analyses were stratified by age and gender of patients,
the AA genotype was associated with a significantly
increased risk of GC (OR 9.500, 95% CI = 3.029-29.796
P = 0.000) at ≤ 60 years and more 2.13-fold at >60 years
(OR 4.452, 95% CI = 1.598-12.404 P = 0.002). The AA
genotype was associated with a significantly increased
risk of GC (OR 10.313, 95% CI = 1.156-91.974 P =
0.012) in the females and was more 1.6-fold greater
than in males (OR 6.273, 95% CI = 2.793-14.089 P =
0.000).
Subsequently, in order to explore whether this SNP is
also associated with EC, we analysed the frequency of
-448A>G. The oesophagus cancer risk related to the
DNMT3A -448A>G genotype are shown in Tables 6
and 7. The allele frequency of -448A among EC patients
and controls was 21.9% versus 19.9%, respectively. The
distributions of -448A>G genotypes in the EC group
Figure 1 Transcription activity analysis of the -448G>A
polymorphism of DNMT3A promoter. Chinese hamster ovary
cells were transiently transfected with luciferase reporter constructs.
The pGL3-basic plasmid lacking promoter sequence was used as a
negative control. The data represents mean – standard deviation
calculated from four independent experiments performed in
triplicates and are expressed as a percentage of the -448A allele
activity. The difference between the -448G and -448A constructs
was significant at P < 0.001 (t-test; n = 6).
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different from those in the controls. Compared with the
reference group, AG+AA genotypes (OR 0.929, 95% CI
= 0.569-1.517 P = 0.769) and AA homozygotes (OR
2.850, 95% CI = 0.920-8.825 P = 0.115) had no greater
risk of EC. When the analyses were stratified by the age
and gender of patients, only the AA genotype was asso-
ciated with an increased risk of EC (OR 7.667, 95% CI =
1.300-45.230 P = 0.026) at >60 years.
Thus, our data reveal important evidence that the pre-
sence of -448A shows that there is a significance likeli-
hood of carcinogenesis occurring in GC patients but not
in EC patients, at least in this Chinese population. The
functional polymorphism in the DNMT3A promoter
modifies the susceptibility to GC and may be a risk
predictor for GC, especially in ≤ 60 year group, which is
the main population affected in China.
Immunohistochemical analysis of DNMT3A in GCs and
pericancerous gastric tissues
Immunoreactivity for DNMT3A was detected in the
cytoplasm but not in the cell membranes of cancer cells
(Figure 3). In order to confirm definitely positive cases
from cases with a leaky background level signal, if more
than 30% of the cells in a tissue sample exhibited cyto-
plasm staining, the sample was considered to show posi-
tive immunoreactivity. DNMT3A immunoreactivity was
detected and overexpressed in 69.64% (39/56) of the
patients.
Discussion
Gastric cancer and esophageal carcinoma are two preva-
lent tumors and is one of the main deaths in Chinese. In
gastric cancers, tumour-suppressor genes (TSGs) are
more frequently inactivated by aberrant DNA methyla-
tion than by mutations [21]. CpG island hepermethyla-
tion of TSGs is associated with a recurrence of early
stage oesophageal carcinoma [22-26]. Increased expres-
sion of DNMT3A and DNMT3B as de novo DNA
methyltransferase are common in many tumours which
implies the that aberrant DNMT3A and DNMT3B
expression are involved in carcinogenesis. Our immuno-
histochemical data showed that the positive rates of
DNMT3A expression in GC tissues were significantly
higher than those of para-cancerous tissues (which agrees
with a previous study of GC paraffin sections [17]) and
therefore shows that SNP of a promoter of a gene may
Figure 2 Sequencing results for the polymerase chain reaction (PCR) products from different -448G>A genotypes. The single nucleotide
polymorphism sites are underlined. The results were completely matched to the corresponding results derived from PCR-restriction fragment
length polymorphism genotyping. A: AA variants (reverse strand), B: GG wild type (reverse strand).
Table 3 DNMT3A -448A>G genotype and allele
frequencies in control subjects
Groups Genotype Allele
GG (%) AG (%) AA (%) A (%) P *
Total 218 (63.0) 118 (34.1) 10 (2.9) 19.9
Age years) 0.09
†
≤60 80 (23.1) 57 (16.5) 4 (1.2) 9.4
>60 138 (39.9) 61 (17.6) 6 (1.7) 10.5
Gender 0.521
‡
Male 152 (43.9) 82 (23.7) 9 (2.6) 14.5
Female 66 (19.1) 36 (10.4) 1 (0.3) 5.5
*Chi-squared test.
† The frequency of A allele in individuals at ≤ 60 years versus > 60 years.
‡ The frequency of A allele in individuals in male versus female.
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gical process. Our previous results suggested that a poly-
morphism at position -579 of the DNMT3B promoter
was associated with a susceptibility to GC [18] but not
EC [27]. To our knowledge, a relationship between the
DNMT3A polymorphism and risk of occurrence and
progression of GC and EC has not so far been reported.
We hypothesized that polymorphisms of DNMT3A
promoter are associated with the risk of cancer. In this
case-control study, we report the association between a
polymorphism in the human DNMT3A promoter and
risk of GC and EC. In 346 healthy control, the allele fre-
quency of -448A is 0.199 and the frequency of -448A>G
(AG+AA) is 0.370, implying that it maybe have a poten-
tial SNP to evaluate the susceptibility to diseases. A luci-
ferase assay showed that the promoter activity of the
construct containing the fragment of DNMT3A of
5’UTR with 448A allele was more than twice as high as
the construct containing the 448G allele in the CHO
cell line, thus supporting the suggestion that the allele is
a functional SNP. The potential mechanism of this asso-
ciation is G >A transition which increases the
DNMT3A promoter activity. The relationship between
more than twofold overexpression of DNMT3A and an
expression of tumour suppressor genes was not con-
firmed but elevated DNMT3A expression does coincide
with some tumour-related genes and includes SFRP5
hypermethylation and transcriptional repression in
paired patient biopsies [28,29]. Knockdown DNMT3A
expression more than doubles the induced 242 genes in
melanoma cells and plays an essential role in melanoma
tumourigenesis [30].
In our analysis of the DNMT3A gene promoter,
-448A>G polymorphism among the GCs, ECs and the
control group drawn from a Chinese population, it was
shown that -448A allele and AA genotype are distribu-
ted in the all three study groups. We found that the A
variant genotype was associated with a significantly
increased risk of GC. AA genotype was associated with
a significantly increased risk of GC at ≤ 60 years and if
the participants were female. Further studies are needed
in order to elucidate the role of DNMT3A variants in
the expression level of DNMT3A in GC patients and
the function of the DNA methylaton. However, this
polymorphism is not associated with a susceptibility to
EC. Although the analyses were stratified by age and
gender of patients, only the AA genotype is associated
with an increased risk of EC at > 60 years.
The present study provides evidence that a SNP in the
DNMT3A promoter region may modify the risk of GC
but not of oesophagus carcinoma. Genetic studies are
Table 4 DNMT3A -448A>G genotype and allele frequencies of case patients and control subjects and their association
with gastric cancer (GC)
Genotype GC
(n = 208)
Control subjects (n = 346) Crude odds ratio
(95% confidence interval)
P value*
No. (%) No. (%)
- 448A>G
GG (ref.) 102 (49.0) 218 (63.0) 1.0
AG 75 (36.1) 118 (34.1) 1.358 (0.936-1.972) 0.107
a
AA 31 (14.9) 10 (2.9) 6.625 (3.128-14.034) 0.000
b
A allele 32.9 19.9
*Chi-square test;.
a versus GG genotype.
b versus GG genotype.
Table 5 Distribution of -448A>G DNMT3A genotypes and
associated odds ratio (OR) in relation to age and gender
in gastric cancer (GC) cases
Genotype GC cases
(%)
Controls
(%)
OR P
value
Age(years)
≤60
GG 40 (19.2) 80(23.1) 1.0
AG 40 (19.2) 57 (16.5) 1.404 (0.806-2.444) 0.230
AA 19 (9.1) 4(1.2) 9.500(3.029-29.796) 0.000
>60
GG 62 (29.8) 138(39.9) 1.0
AG 35 (16.8) 61 (17.6) 1.277 (0.765-2.132) 0.349
AA 12 (5.8) 6 (1.7) 4.452(1.598-12.404) 0.002
Gender
Male
GG 70(33.7) 152(43.9) 1.0
AG 61(29.3) 82 (23.7) 1.615(1.045-2.498) 0.031
AA 26(12.5) 9 (2.6) 6.273(2.793-14.089) 0.000
Female
GG 32(15.4) 66(19.1) 1.0
AG 14(6.7) 36 (10.4) 0.802(0.380-1.694) 0.563
AA 5(2.4) 1 (0.3) 10.313(1.156-
91.974)
0.012
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similar risk factors develop different kinds of tumours.
Different genetics factors, including tumour suppressor
genes and silencing catalyzed by de novo methylatrans-
ferases, were involved in the tumourigenesis of different
types of tumours. Although it has been reported that
several tumour suppressor genes, such as p16 [31,32], E-
cadherin [9,33] TIMP3 [34], DLC1 [35,36] and RUNX3
[37,38] silence GC and EC, only MINT25, RORA,
GDNF, ADAM23, PRDM5, MLF1 showed frequent dif-
ferential methylation in GC [39] which implies that dif-
ferent genetic and epigenetic mechanism are involved in
the development and progression of these two tumour
types. Then, DNMT3A expression was detected in AA,
GA, and GG variants genotype carriers in GC and EC
patients (Additional File 1). There was higher DNMT3A
expression in GA genotype carriers of GCs but lower
DNMT3A in GA carriers of ECs. AA homozygote was
not found in the detected cases, possibly because the
examined group was not large enough. These data sug-
gested that DNMT3A may play a role in the progression
of gastric cancer and this finding needs to be confirmed
by a larger study.
In addition, as genetic polymorphisms often vary in
tissues in different ethnic groups, further studies are
needed in order to clarify the association of the
DNMT3A polymorphism with GC in diverse ethnic
Table 6 DNMT3A -448A>G genotype and allele frequencies of case patients and control subjects and their association
with oesophagus carcinoma (EC)
Genotype EC (n = 96) Control subjects (n = 241) Crude odds ratio (95% confidence interval) P value*
No. (%) No. (%)
- 448A>G
GG (ref.) 61 (63.5) 149 (61.8) 1.0
AG 28 (29.2) 86 (35.7) 0.795 (0.473-1.338) 0.388
c
AA 7 (7.3) 6 (2.5) 2.850 (0.920-8.825) 0.115
d
A allele 21.9 19.9
*Chi-squared test;
c versus GG genotype.
d versus GG genotype.
Table 7 Distribution of -448A>G DNMT3A genotypes and
associated odds ratio (OR) in relation to age and gender
in oesophagus carcinoma (EC) cases
Genotype EC cases (%) Controls (%) OR P value
Age(years)
≤60
GG 43 (44.8) 80 (33.2) 1.0
AG 15 (15.6) 57 (23.7) 0.490 (0.248-0.965) 0.037
AA 3 (3.1) 4 (1.7) 1.395 (0.298-6.523) 0.985
>60
GG 18 (18.7) 69 (28.6) 1.0
AG 13 (13.5) 29 (12.0) 1.718 (0.746-3.960) 0.201
AA 4 (4.2) 2 (0.8) 7.667(1.300-45.230) 0.026
Gender
Male
GG 46 (47.9) 96(39.8) 1.0
AG 20 (20.8) 59 (24.5) 0.707 (0.382-1.311) 0.271
AA 5 (5.2) 5 (2.1) 2.087 (0.575-7.570) 0.428
Female
GG 15 (15.6) 53(22.0) 1.0
AG 8 (8.3) 27 (11.2) 1.047 (0.395-2.776) 0.927
AA 2 (2.1) 1 (0.4) 7.067 (0.599-83.374) 0.140
Figure 3 DNMT3A expression in gastric cancerous and
corresponding paracancerous tissues. DNMT3A is shown as
brown and is well distributed in the cytoplasm. (A, B)
Immunohistochemical staining of DNMT3A in paracancerous tissues
of GCs (A, ×100 and B, ×400). (C, D) Immunohistochemical staining
of DNMT3A in cancerous tissues of gastric cancer cases (C, ×100; D
×400).
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variants and their biologic function are also needed in
order to understand the role of DNMT3A polymorph-
isms in determining the risk of cancer. The current
study suggested that at least some DNMT3A poly-
morphisms, including the DNMT3A promoter SNP,
may play different roles in the development and pro-
gression of these two tumor types. The importance of
t h eD N M T 3 Ag e n ei nt h er e g u l a t i o no fD N Am e t h y l a -
tion and gene expression makes it attractive for further
study of other cancers and it could be a useful marker
for epidemiological study.
Conclusion
In conclusion, our study provides the first evidence that
this newly identified polymorphism of the DNMT3A
promoter is significantly associated with an increased
risk of GC in this study population. The potential
mechanism for the higher risk associated with the var-
iants may be an increased activity of G > A. These
results suggest that the polymorphism of DNMT3A
could be used as an important marker of genetic sus-
ceptibility to GC, although additional studies using lar-
ger sample sizes are required to confirm our findings.
Additional file 1: Figure S1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-7015-8-12-
S1.DOC]
Additional file 2: Supplementary information.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-7015-8-12-
S2.TIFF]
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